Global High Content Screening Market-Segmented by Product, Application, End-user, and by Geography-Growth, Trends, and Forecast (2018-2023)
Global High Content Screening Market Report provides pin-point analysis for changing competitive dynamics and growing investment opportunities.
(EMAILWIRE.COM, June 14, 2018 ) Global High Content Screening Market 2018-2023:
The high content screening market is expected to register a CAGR of around 10%, during the forecast period, 2018 to 2023. High-content analysis (HCA) or high-content screening (HCS) defines a set of programmed diagnostic methods using integrated microscopy, image processing, and visualization gears to mine data from cells or cell populations and report quantitative results. Over the past five years, a majority of HTS laboratories have adopted high-content screening (HCS) in their operations. As HTS laboratories have sought more biologically-relevant assays, cell-based assays, and high content screening technologies have become more widespread.
Major players - BECTON DICKINSON, BIO-RAD LABORATORIES, CELL SIGNALLING TECHNOLOGIES, DANAHER CORPORATION, GE HEALTHCARE, GENEDATA AG, MERCK MILLIPORE, PERKIN ELMER, THERMO FISHER SCIENTIFIC, AND YOKOGAWA ELECTRIC CORPORATION, amongst others.
Get Sample Copy of Global High Content Screening Market @ http://orbisresearch.com/contacts/request-sample/2131423
Companies Mentioned:
Becton Dickinson, Bio-Rad Laboratories, Cell Signalling Technologies, Danaher Corporation, Ge Healthcare, Genedata Ag, Merck Millipore, Perkin Elmer, Thermo Fisher Scientific, Yokogawa Electric Corporation
Technological Advancements in High Content Screening Technologies
A variety of assay technologies continue to be developed for high-content screening. These include cell-based assays, surrogate systems using microbial cells, such as yeast and bacterial two-hybrid and three-hybrid systems, and systems to measure nucleic acid-protein and receptor-ligand interactions. Modifications have been developed for cell-free, homogeneous assay systems, such as time-resolved fluorescence, fluorescence polarization, and the scintillation proximity assay. Innovations in engineering and chemistry have led to delivery systems for nanoliter volumes and sensitive biosensors for ultra-high-content screening conducted in nanoliter and picoliter volumes. Spectroscopic methods have been extended to read single-molecule fluorescence. Technologies are being developed to identify new targets from genomic information to design the next generation of screens. These advances will help drive the market in the future. Other factors, such as increase in the government funding and private investments and increase in emphasis on diagnosis will boost the market growth in the future.
High Costs of Initial Investment
In case of High Content Screening, the capital required to setup up the equipment for high content screening is very expensive as there is a lot of high-end biotechnology is involved. Also, the cost of labor is very high a sit requires very skilled labor, which is very expensive as the operations involved are complex and high-end laboratory professionals are often highly paid. Along with this, the lack of properly trained professionals may act as a restraining factor for the growth of high content screening market.
North America to Dominate the Market
In 2017, North America is expected to account for the largest share of the market followed by Europe. This regional segment is expected to register the highest CAGR during the forecast period. In APAC and European regions, the market is going to grow because of the increasing awareness about the efficiency of high content screening. These regions will witness considerable growth in the forecast period.
Enquire Before Buying Global High Content Screening Market Report @ http://orbisresearch.com/contacts/enquiry-before-buying/2131423
Key Developments in the Market
March 2017 - Becton Dickinson, Bio-Rad Laboratories, Cell Signalling Technologies, Danaher Corporation, GE Healthcare, Genedata AG, Merck Millipore, and Perkin Elmer, among others
Reasons to Purchase this Report
Current and future High Content Screening Market outlook in the developed and emerging markets
Analysis of various perspectives of the market with the help of Porter’s five forces analysis
The segment that is expected to dominate the market
Regions that are expected to witness the fastest growth during the forecast period
Identify the latest developments, market shares, and strategies employed by the major market players
3 months analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.
Table Of Content:
1. Introduction
2. Research Approach and Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
Continued…
Place Purchase Order for Global High Content Screening Market Report @ http://orbisresearch.com/contact/purchase/2131423
The high content screening market is expected to register a CAGR of around 10%, during the forecast period, 2018 to 2023. High-content analysis (HCA) or high-content screening (HCS) defines a set of programmed diagnostic methods using integrated microscopy, image processing, and visualization gears to mine data from cells or cell populations and report quantitative results. Over the past five years, a majority of HTS laboratories have adopted high-content screening (HCS) in their operations. As HTS laboratories have sought more biologically-relevant assays, cell-based assays, and high content screening technologies have become more widespread.
Major players - BECTON DICKINSON, BIO-RAD LABORATORIES, CELL SIGNALLING TECHNOLOGIES, DANAHER CORPORATION, GE HEALTHCARE, GENEDATA AG, MERCK MILLIPORE, PERKIN ELMER, THERMO FISHER SCIENTIFIC, AND YOKOGAWA ELECTRIC CORPORATION, amongst others.
Get Sample Copy of Global High Content Screening Market @ http://orbisresearch.com/contacts/request-sample/2131423
Companies Mentioned:
Becton Dickinson, Bio-Rad Laboratories, Cell Signalling Technologies, Danaher Corporation, Ge Healthcare, Genedata Ag, Merck Millipore, Perkin Elmer, Thermo Fisher Scientific, Yokogawa Electric Corporation
Technological Advancements in High Content Screening Technologies
A variety of assay technologies continue to be developed for high-content screening. These include cell-based assays, surrogate systems using microbial cells, such as yeast and bacterial two-hybrid and three-hybrid systems, and systems to measure nucleic acid-protein and receptor-ligand interactions. Modifications have been developed for cell-free, homogeneous assay systems, such as time-resolved fluorescence, fluorescence polarization, and the scintillation proximity assay. Innovations in engineering and chemistry have led to delivery systems for nanoliter volumes and sensitive biosensors for ultra-high-content screening conducted in nanoliter and picoliter volumes. Spectroscopic methods have been extended to read single-molecule fluorescence. Technologies are being developed to identify new targets from genomic information to design the next generation of screens. These advances will help drive the market in the future. Other factors, such as increase in the government funding and private investments and increase in emphasis on diagnosis will boost the market growth in the future.
High Costs of Initial Investment
In case of High Content Screening, the capital required to setup up the equipment for high content screening is very expensive as there is a lot of high-end biotechnology is involved. Also, the cost of labor is very high a sit requires very skilled labor, which is very expensive as the operations involved are complex and high-end laboratory professionals are often highly paid. Along with this, the lack of properly trained professionals may act as a restraining factor for the growth of high content screening market.
North America to Dominate the Market
In 2017, North America is expected to account for the largest share of the market followed by Europe. This regional segment is expected to register the highest CAGR during the forecast period. In APAC and European regions, the market is going to grow because of the increasing awareness about the efficiency of high content screening. These regions will witness considerable growth in the forecast period.
Enquire Before Buying Global High Content Screening Market Report @ http://orbisresearch.com/contacts/enquiry-before-buying/2131423
Key Developments in the Market
March 2017 - Becton Dickinson, Bio-Rad Laboratories, Cell Signalling Technologies, Danaher Corporation, GE Healthcare, Genedata AG, Merck Millipore, and Perkin Elmer, among others
Reasons to Purchase this Report
Current and future High Content Screening Market outlook in the developed and emerging markets
Analysis of various perspectives of the market with the help of Porter’s five forces analysis
The segment that is expected to dominate the market
Regions that are expected to witness the fastest growth during the forecast period
Identify the latest developments, market shares, and strategies employed by the major market players
3 months analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.
Table Of Content:
1. Introduction
2. Research Approach and Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
Continued…
Place Purchase Order for Global High Content Screening Market Report @ http://orbisresearch.com/contact/purchase/2131423
Contact Information:
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results